Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
BioCryst (Nasdaq:BCRX) will present new hereditary angioedema (HAE) data at the 2026 EAACI Annual Meeting in Istanbul from June 12-15, 2026.
The company will share seven abstracts, including six on ORLADEYO (berotralstat) and one on navenibart, covering clinical trial and real-world outcomes across pediatric, adolescent and adult HAE populations.
BioCryst (Nasdaq:BCRX) will present new real-world evidence on pediatric hereditary angioedema (HAE) at ISPOR 2026 in Philadelphia, May 17–20, 2026.
Two posters analyze U.S. insurance claims and caregiver insights, showing higher healthcare resource use in children with HAE and substantial time and quality-of-life impacts on caregivers.
BioCryst (Nasdaq: BCRX) reported Q1 2026 results: ORLADEYO net revenue $148.3M (+11% y/y; +21% comparable excl. Europe). The company recorded a GAAP operating loss $701.6M driven by a $697.8M acquired in‑process R&D charge from the Astria acquisition.
BioCryst closed a European license for navenibart with $70M upfront, up to $275M in milestones, and 18–30% tiered royalties. Cash and investments totaled $260.8M (pro forma $330.8M including $70M license proceeds). 2026 ORLADEYO revenue guidance remains $625M–$645M.
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units to six newly hired employees covering an aggregate of 61,750 shares, effective May 1, 2026.
The RSUs were issued under Nasdaq Listing Rule 5635(c)(4), vest in four equal annual installments beginning on the one-year anniversary, and are subject to the Inducement Equity Incentive Plan and individual RSU agreements.
BioCryst (Nasdaq: BCRX) granted an Irish affiliate of Neopharmed Gentili an exclusive license to commercialize navenibart for hereditary angioedema in Europe. BioCryst will receive $70M upfront, up to $275M in regulatory and sales milestones, and tiered royalties of 18%–30%.
Navenibart is an investigational long‑acting plasma kallikrein inhibitor; BioCryst’s Phase 3 program is on track to support a U.S. regulatory filing by the end of 2027. The deal follows the 2025 sale of European ORLADEYO commercial rights to Neopharmed Gentili and aims to align regional commercialization and strengthen BioCryst’s near‑term finances.
BioCryst (NASDAQ:BCRX) will present at two investor conferences in May and June 2026. The company is scheduled to speak at the Bank of America Health Care Conference in Las Vegas on May 12, 2026 at 4:40 p.m. ET and at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 3:45 p.m. ET.
Live audio webcasts and replays will be available in the Investors & Media section of BioCryst’s website.
BioCryst (Nasdaq: BCRX) will report its first quarter 2026 financial results on Wednesday, May 6, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Investors can access the live call by phone or via a webcast with replay available on the company's investor website.
BioCryst (Nasdaq: BCRX) appointed Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer effective April 6, 2026. Menon joins from Alnylam, where he oversaw global clinical development and helped secure FDA approval of AMVUTTRA.
The company cited the Astria acquisition and the navenibart program moving toward a potential BLA as drivers for sharpening R&D strategy, balancing capital allocation, and preparing for additional rare‑disease launches.
BioCryst (Nasdaq: BCRX) granted inducement equity to 12 newly hired employees on April 1, 2026 under Nasdaq Listing Rule 5635(c)(4). The compensation committee awarded 33,950 stock options and 123,350 RSUs as of the grant date.
The options carry an exercise price of $9.38 (closing price on the grant date), a 10-year term, and both awards vest in four equal annual installments starting on the one-year anniversary, subject to continued service and plan terms.
BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date and are subject to the company’s Inducement Equity Incentive Plan and individual RSU agreements.